Leuthold Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Leuthold Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,467	Closed	-$2.17M	–	222
2025 Q1	$2.17M	Buy	+17,467	New	+$2.28M	0.28%	130

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Leuthold Group's JAZZ Position: Q2 2025 in Review

Leuthold Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 17,467 shares — an estimated $2.17M sold.

Leuthold Group first reported a position in JAZZ in Q1 2025 and held it in 1 quarter. The position peaked at $2.17M in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

Leuthold Group reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Leuthold Group sold 17,467 Jazz Pharmaceuticals shares in Q2 2025, an estimated $2.17M.
Leuthold Group first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Leuthold Group's Jazz Pharmaceuticals position peaked at $2.17M in Q1 2025.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Leuthold Group's 13F filing for Q2 2025, filed 13 Aug 2025.